The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated guidance for women using GLP-1 receptor agonists.
Women are advised not to use these medicines during pregnancy, when trying to conceive or while breastfeeding, due to limited safety data on potential risks to the fetus. The MHRA states that those who become pregnant while on treatment should discontinue use and consult a healthcare professional.
In particular, the MHRA notes that tirzepatide (Mounjaro) may reduce the effectiveness of oral contraceptives in individuals with a higher BMI. A secondary, non-oral contraceptive method is recommended during the first four weeks of treatment and after any dose escalation.
The guidance follows growing concerns about inappropriate use of GLP-1 medicines outside licensed indications and without sufficient clinical oversight. The MHRA is also encouraging healthcare professionals and patients to report suspected adverse effects or counterfeit products via the Yellow Card scheme.
Dr Alison Cave, MHRA chief safety officer, said, “Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight and have not been assessed to be safe when used in this way. Our guidance offers patients a ‘one stop shop’ for our up-to-date advice on how to use these powerful medicines safely.”
